Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

      Eloxx Pharmaceuticals, Inc.

      News provided by

      Eloxx Pharmaceuticals, Inc.

      Nov 16, 2026, 07:00 ET

      Share this article

      Share this article


      • Dosed first two patients in global Phase 2b EXACT study of exaluren in nonsense mutation Alport syndrome; topline data from the 16-week placebo-controlled portion expected in mid-2027
      • Finalized protocol and received IND clearance for Phase 2 EXPRESS study of exaluren in nonsense mutation autosomal dominant polycystic kidney disease (ADPKD); first patient expected to be dosed in the third quarter of 2027
      • Expanded leadership team with appointment of T.R. Srinivas, M.D., as SVP, Chief Medical Officer
      • Cash and cash equivalents of $56.3 million as of September 30, 2026

      ARLINGTON, Mass., Nov. 16, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

      "The third quarter marked important progress for Eloxx, as we dosed the first two patients in our Phase 2b EXACT study in nonsense mutation Alport syndrome. With the EXPRESS protocol finalized and IND clearance in hand, we now have two programs in rare kidney disease," said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.

      Recent Business Highlights

      • Phase 2b EXACT study in nonsense mutation Alport syndrome (NMAS)
        • In September 2026, the Company announced that the first two patients had been dosed in its Phase 2b EXACT study (NCT07523581), a global, randomized, placebo-controlled, delayed-start trial of exaluren designed to enroll 24 patients with Alport syndrome caused by nonsense mutations in the COL4A3, COL4A4 or COL4A5 genes. The primary efficacy endpoint of the initial 16-week placebo-controlled portion of the trial is the change in podocyte foot process effacement, measured as the change in filtration slit density on kidney biopsies, in non-U.S. pediatric patients and all adult patients.
        • An earlier open-label Phase 2a study observed structural improvements, including reduced foot process effacement and improved GBM width, in kidney biopsies in all three participants.
        • The Company expects to report topline data from the 16-week placebo-controlled portion in mid-2027 and final 32-week data by the end of 2027.
      • Phase 2 EXPRESS study in nonsense mutation ADPKD (nmADPKD)
        • The Company finalized the design of the 52-week EXPRESS study. EXPRESS is designed as a global, randomized, placebo-controlled trial in approximately 60 adults with genetically confirmed nonsense mutations in the PKD1 or PKD2 genes, who will be randomized 1:1 to receive exaluren or placebo for 52 weeks. The primary endpoint is the annualized rate of change in height-adjusted total kidney volume (htTKV), as measured by magnetic resonance imaging. Eloxx estimates that 40,000 to 50,000 people in the United States have ADPKD caused by nonsense mutations.
        • On October 29, 2026, the Company announced FDA clearance of the IND for exaluren in nmADPKD, enabling it to open U.S. clinical sites.
        • The Company expects to dose the first patient in the third quarter of 2027 and to report 52-week topline data in the first half of 2029.  In pre-IND feedback reported by Eloxx in October, FDA indicated that a substantial and durable effect on kidney volume growth, with supporting kidney function and safety data, could be a potential basis for Breakthrough Therapy Designation. Any designation would depend on the clinical results and further FDA review.
      • Expanded leadership team and Board of Directors
        • In October 2026, the Company appointed T.R. Srinivas, M.D., as Senior Vice President and Chief Medical Officer, responsible for leading its renal medical strategy across its Alport syndrome and ADPKD programs. Dr. Srinivas joined Eloxx from Novartis, where he held U.S. Medical Affairs leadership responsibilities for ADPKD product development.
        • Also in October 2026, the Company's Board of Directors appointed Geno Germano as a director, effective October 19, 2026. Mr. Germano brings more than 35 years of biopharmaceutical development and commercialization leadership. He most recently served as President and Chief Executive Officer of Elucida Oncology, and previously served as President of Intrexon (now Precigen) and as Group President of Pfizer's Global Innovative Pharmaceutical business. He currently serves as Chairman of Entera Bio and as a director of Precision BioSciences and Harmony Biosciences and has previously served on the boards of Sage Therapeutics, Bioverativ, The Medicines Company and Zoetis.

      Third Quarter 2026 Financial Results

      In May 2026, the Company effected a one-for-eleven reverse stock split of its common stock and reduced its authorized shares of common stock from 500,000,000 to 100,000,000. All share and per-share amounts in this press release reflect the reverse stock split.

      Research and development (R&D) expenses were $4.0 million for the three months ended September 30, 2026, compared to a net credit of $0.3 million for the same period in 2025. The increase was primarily related to higher clinical trial expenses associated with the initiation of the Phase 2b EXACT study, as well as increases in personnel costs. R&D expenses for the third quarter of 2025 were reduced by a $0.9 million write-off of accounts payable balances with certain vendors under settlement agreements.

      General and administrative (G&A) expenses were $1.9 million for the three months ended September 30, 2026, compared to $0.5 million for the same period in 2025. The increase was primarily related to higher professional and consulting fees, including legal, audit and tax fees, increased personnel costs, and higher facility and other overhead costs.

      Other income, net was $0.4 million for the three months ended September 30, 2026, compared to other expense, net, of $0.1 million for the same period in 2025. The change was primarily related to higher interest income on increased cash balances following the June 2026 public offering and lower interest expense.

      Net loss for the three months ended September 30, 2026, was $5.5 million, or $(0.49) per share, which included $0.2 million in stock-based compensation, compared to a net loss of $0.4 million, or $(0.58) per share, for the same period in 2025. For the nine months ended September 30, 2026, net loss was $13.8 million, or $(1.83) per share, compared to $4.0 million, or $(9.12) per share, for the same period in 2025.

      Cash position. As of September 30, 2026, the Company had cash and cash equivalents of $56.3 million, compared to $62.0 million as of June 30, 2026. The Company believes its cash and cash equivalents will be sufficient to fund its operations into 2028.

      About Eloxx Pharmaceuticals

      Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a clinical-stage biopharmaceutical company developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins. Eloxx's lead product candidate, exaluren, is being developed for the treatment of rare kidney diseases, including nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD). Eloxx has also exclusively licensed its product candidate, ZKN-013, to Almirall, S.A., which is developing it for the treatment of rare dermatological diseases associated with nonsense mutations.

      For more information, please visit www.eloxxpharma.com. The corporate presentation and investor event information are available at www.eloxxpharma.com/investors/.

      Forward-Looking Statements

      This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including, without limitation, statements regarding the sufficiency of the Company's cash and cash equivalents to fund its operations; the expected timing of enrollment in, and topline and final data from, the Phase 2b EXACT study of exaluren in nonsense mutation Alport syndrome; the expected timing of initiation of, and topline data from, the planned Phase 2 EXPRESS study of exaluren in nonsense mutation ADPKD; the potential for exaluren to receive Breakthrough Therapy Designation or to be eligible for accelerated approval or other expedited regulatory pathways; the potential benefits of orphan drug designation; the Company's ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market; the Company's collaboration with Almirall and the potential to receive milestone and royalty payments; and the potential of the Company's product candidates to treat diseases caused by nonsense mutations, are forward-looking statements. Forward-looking statements can be identified by words such as "aim," "may," "will," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "potential," "seeks," or "continue," or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and are subject to known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied due to various important factors, including, but not limited to, the Company's need for and ability to obtain additional capital; the uncertainty of timing, results and expense related to the clinical and regulatory development process; the fact that results from preclinical studies and early clinical trials are not necessarily predictive of future results; and other important factors discussed under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and elsewhere in the Company's filings with the SEC, accessible on the SEC's website at www.sec.gov and on the "Financials & Filings" page of the Company's website. All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements contained herein.

      Contact

      Investor Relations
      Eloxx Pharmaceuticals, Inc.
      [email protected]
      (781) 577-5300

      ELOXX PHARMACEUTICALS, INC.

      Condensed Consolidated Statements of Operations

      (in thousands, except share and per share amounts)

      (unaudited)



      Three Months Ended

      Nine Months Ended


      September 30,

      September 30,


      2026


      2025


      2026


      2025


      Operating expenses:













      Research and development

      $

      4,028


      $

      (250)


      $

      8,528


      $

      1,158


      General and administrative


      1,925



      535



      5,671



      1,931


      Total operating expenses


      5,953



      285



      14,199



      3,089


      Loss from operations


      (5,953)



      (285)



      (14,199)



      (3,089)


      Other (income) expense, net


      (410)



      66



      (400)



      862


      Net loss

      $

      (5,543)


      $

      (351)


      $

      (13,799)


      $

      (3,951)















      Net loss per share, basic and diluted

      $

      (0.49)


      $

      (0.58)


      $

      (1.83)


      $

      (9.12)


      Weighted average number of shares of common stock
      and pre-funded warrants used in computing net loss
      per share, basic and diluted


      11,404,791



      604,278



      7,551,283



      433,358


      ELOXX PHARMACEUTICALS, INC.

      Condensed Consolidated Balance Sheet Data

      (in thousands)

      (2026 unaudited)



      September 30,

      December 31,


      2026


      2025


      Cash and cash equivalents

      $

      56,264


      $

      4,785


      Total assets

      $

      58,261


      $

      5,270


      Total current liabilities

      $

      17,192


      $

      17,177


      Total stockholders' equity (deficit)

      $

      41,069


      $

      (11,907)


      SOURCE Eloxx Pharmaceuticals, Inc.

      Modal title

      Also from this source

      Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference

      Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference

      Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, ...

      Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD

      Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD

      Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, ...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.